GenScript to host virtual summit on genetic and cellular engineering
Dr. Alexandre marson, PhD, director of the Gladstone-UCSF Institute for Genomic Immunology, will present a talk titled “Reprogramming Human T Cells with CRISPR”. Dr. Marson’s lab uses genomic and gene editing approaches to address the consequences of coding and non-coding genetic variation in immune cell function and autoimmune disease risk and to genetically engineer human immune cells to target cancer, autoimmunity and infectious diseases.
“We are honored to partner with the Marson lab with our single-stranded DNA service since 2018 and to see the tremendous progress the team has made as a leader in CRISPR-based non-viral CAR-T engineering,” said declared Ray chen, Doctorate, president of GenScript Life Science Group. “We welcome Dr. Marson as the keynote speaker at the Summit to address this important topic.”
Joseph melenhorst, PhD, director of the Parker Institute for Cancer Immunotherapy Biomarker Program at University of Pennsylvania, will present with the closing session, “Response to second generation CAR T cell therapy: Tango needs (at least) two.” The presentation will highlight findings in elucidating intrinsic determinants of T cells and Tumor Cell Efficiency CAR T Cells, and will be followed by a question-and-answer session.
“As a leader in gene synthesis and editing technologies, GenScript has been fortunate to work with many pioneering scientists in cellular and genetic engineering,” Chen added. “We are delighted to bring together Dr Melenhorst and many of these leaders for this summit to share their research, especially at a time when rapid advances in cell and gene engineering are poised to dramatically improve cancer treatment. and many other diseases.
Other leading researchers speaking at the Summit include:
- Ben kleinstiver, PhD, assistant professor, Massachusetts General hospital and Harvard Medical School
- Jean Zuris, PhD, Associate Director, Editing Technologies at Editas Medicine
- Rama Shivakumar, Technical Applications Manager at MaxCyte Inc.
- Shondra M. Pruett-Miller, PhD, Director, St. Jude Children’s Research Hospital Cancer Center
- Sam sternberg, PhD, Assistant Professor, Department of Biochemistry and Molecular Biophysics, Columbia university
- Niren murthy, PhD, Professor, Department of Bioengineering UC Berkeley – Institute for Innovative Genomics
- Gal Cafri, PhD, Immunotherapy and Genetic Engineering Group Leader, Sheba Medical Center
- Ramarao vepachedu, PhD, Development Scientist IV, Leidos Biomedical Research, Inc.
- Matthew Porteus, MD, PhD, professor, Stanford University, Medicine School
- Killian S. Hanlon, PhD, researcher, Harvard Medical School; Massachusetts General hospital
- Karla Camacho Soto, PhD, senior scientist, Merck
- Ye Liu, Senior Director of Gene Transfer Technologies, REGENXBIO Inc.
To register for the event and learn more, please visit labroots.com.
About GenScript Biotech Corporation
GenScript Biotech Corporation (stock code: 1548.HK) is a global biotechnology group. Based on its advanced gene synthesis technology, GenScript has developed four major platforms, including the Global Cell Therapy Platform, Biologics Development and Manufacturing Organization (CDMO) Platform, the contract research organization (CRO) platform and the industrial synthesis products platform.
GenScript was founded in New Jersey, United States, in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript’s business operations span over 100 countries and regions around the world, with legal entities located in the United States, Mainland China, Hong Kong, Japan, Singapore, Netherlands, and Ireland. GenScript has provided premium, convenient and reliable products and services to over 100,000 customers.
GenScript owns several intellectual property rights and technical secrets, including over 100 patents and over 270 patent applications. From December 31, 2019, GenScript’s products and services have been cited in 42,200 peer-reviewed journal articles around the world.
For more information, visit www.genscript.com.